Recruiting

Virtual Programming

Sponsor:

Scott G. Thomas

Code:

NCT04999410

Conditions

Apparently Healthy Adults Cycling Performance

Eligibility Criteria

Sex: All

Age: 18 - 45

Healthy Volunteers: Accepted

Interventions

High Intensity Interval Training

Study Details

Brief summary:

High Intensity Interval Training (HIIT) studies are required to determine the optimal training protocol to improve time trial(TT) performance. Data collection for this study will be conducted virtually through the use of a software platform (www.trainerroad.com) by people in their homes on cycle ergometers. Investigators will recruit people who are familiar with cycle exercise training and have their own equipment. By using a virtual platform to collect data, investigators will extend our reach to include a much larger and diverse sample of adult men and women up to age 45 years. In addition, the software platform will allow participants to train from the safety of their home, preventing the risk of exposure to COVID19.

OBJECTIVES O1: The primary objective of this study is to determine the influence of interval work-bout duration on TT performance when total mechanical work is matched.

O2: The secondary objective of the study is to determine the influence of work-bout duration on TT performance when work is matched by effort.

HYPOTHESIS H1: long duration bouts of HIIT will lead to greater improvements in performance compared to short duration bouts due to larger total amount of work completed during the interval sessions.

H2: HIIT will lead to equivalent improvements in performance when work is matched by the participant's rating of effort.

Conditions

Apparently Healthy Adults Cycling Performance

Study ID

NCT04999410

Start date

Nov 20, 2020

Status verified date

Aug, 2021

Completion date

Oct 31, 2021

Anticipated

Primary completion date

Oct 31, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 45

Healthy Volunteers: Accepted

Inclusion Criteria:

1. between the ages of 18 and 45 years of age
2. cycling for a minimum of 3 times per week for the previous 6-months.

Exclusion Criteria:
3. an injury in the previous 6-months preventing them from completing their normal training routine
4. presence of pathology including cardiovascular diseases (heart attack, hypertension), neurological conditions (stroke, etc.) or metabolic conditions (diabetes).

Participants will be asked to confirm their health status when they complete the intake survey.

Study Design

Enrollment

140 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Long-HITT

Long work bout durations (4 minutes) on cycle ergometers or home trainers

active comparator: Medium HIIT-L

Medium duration work bouts (2 minutes) with intensity matched to the Long-HITT intensity

active comparator: Medium HIIT-H

Medium duration work bouts (2 minutes) with intensity at 30% of the difference between Wmax and mean TT power outputs

active comparator: Short HIIT

Short duration work bouts (30 seconds) with intensity at 50% of the difference between Wmax and mean TT power outputs

Interventions

High Intensity Interval Training

Interventions will contrast alternative training protocols

Primary outcome measure

  • Time Trial Performance [ Time Frame: 1 week before and 1 to 3 days after interventions ]

Central Contacts and Locations

Central contacts

Scott G Thomas, PhD

6475196957scott.thomas@utoronto.ca

Michael Rosenblat, MSc

778-782-9084m.rosenblat@mail.utoronto.ca

Locations

Goldring High Performance Sport Centre

Recruiting

Toronto, Ontario, Canada, M5S2W6

Contacts

Scott Thomas

6475196957scott.thomas@utoronto.ca

Michael Rosenblat, PhD (Cand)

778-782-9084m.rosenblat@mail.utoronto.ca

Principal Investigator:

Bruno R da Costa, PhD

More Information

Sponsor

Scott G. Thomas

Last update posted

Aug 10, 2021

Last verified

Aug, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Scott G. Thomas on 2021-08-10.